17:35 , Mar 15, 2019 |  BC Week In Review  |  Company News

Principia reacquires immunoproteasome inhibitors from AbbVie

Principia and AbbVie agreed to end a 2017 deal to develop oral immunoproteasome inhibitors to treat autoimmune disorders. Principia Biopharma Inc. (NASDAQ:PRNB), which regained rights to the program, said AbbVie Inc. (NYSE:ABBV) had determined that...
16:49 , Mar 12, 2019 |  BC Extra  |  Politics & Policy

NCI’s Sharpless to become acting FDA commissioner

Ned Sharpless, director of the National Cancer Institute, will serve as acting FDA commissioner when Scott Gottlieb leaves the agency in mid-April. Speaking at a congressional hearing Tuesday, HHS Secretary Alex Azar announced that Douglas...
00:34 , Mar 7, 2019 |  BC Extra  |  Financial News

Biotech indexes continue slide after Gottlieb resignation

Biotech indexes continued to fall Wednesday after taking a sharp dive Tuesday in reaction to the resignation of FDA Commissioner Scott Gottlieb (see "Gottlieb Resigning as FDA Commissioner" ). Since its close on Monday, the...
20:21 , Mar 5, 2019 |  BC Extra  |  Politics & Policy

Gottlieb resigning as FDA commissioner

Scott Gottlieb is resigning as FDA commissioner. He is expected to remain at the agency about a month, an agency spokesperson told BioCentury. Gottlieb was sworn in as the agency’s twenty third commissioner on May...
01:42 , Mar 1, 2019 |  BC Week In Review  |  Company News

Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Feb. 27 with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG). BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide...
00:50 , Feb 28, 2019 |  BC Extra  |  Financial News

Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Wednesday with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG). BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide and...
17:17 , Feb 22, 2019 |  BC Week In Review  |  Company News

Bayer claims full rights to Vitrakvi from Lilly’s Loxo

Eli Lilly and Co. (NYSE:LLY) gained two fewer assets from its acquisition of Loxo Oncology Inc. than planned, as Loxo partner Bayer AG (Xetra:BAYN) said Feb. 15 it will exercise a change-of-control option to acquire...
23:51 , Feb 15, 2019 |  BC Extra  |  Company News

Bayer claims full rights to Vitrakvi from Lilly’s Loxo

Eli Lilly and Co. (NYSE:LLY) gained two fewer assets from its acquisition of Loxo Oncology Inc. than planned, as Loxo partner Bayer AG (Xetra:BAYN) said Friday it will exercise a change-of-control option to acquire full...
00:14 , Feb 9, 2019 |  BioCentury  |  Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
20:48 , Feb 8, 2019 |  BC Week In Review  |  Company News

Lilly dropping Hanmi's BTK inhibitor

Eli Lilly and Co. (NYSE:LLY) discontinued from its pipeline a Bruton's tyrosine kinase (Btk) inhibitor it had licensed from Hanmi Pharmaceutical Co. Ltd. (KSE:128940). The pharma announced the pipeline update in its 4Q18 earnings presentation...